Search clinical trials for: TTI-622 PD-1 Inhibitor

Total 5232 results

Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Capital Medical University
Duke University

Completed

Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Neoplasms

China
Capital Medical University
Duke University; Geneplus-Beijing Co. Ltd.

Completed

Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

Neoplasms | Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; Sun Yat-sen University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Plaque, Atherosclerotic | Programmed Cell Death Protein 1 Inhibitor

China
Wuxi People's Hospital

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Cancer | PD-L1 Gene Mutation

China
Pain Therapeutics

Completed

Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

Metastatic Melanoma

Israel
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
RenJi Hospital

Not yet recruiting

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (sPLENTY-pc)

Pediatric Cancer | Liver Cancer | Hepatoblastoma | Pediatric Solid Tumor | Transitional Cell Tumor

China
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
Xuhua Duan

Recruiting

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

NSCLC

China
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Qingdao Central Hospital

Recruiting

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Overall Survival

China
Peking Union Medical College

Recruiting

Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients

Non-small Cell Lung Cancer

China
TaiwanJ Pharmaceuticals Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis

Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
Wuhan Union Hospital, China

Recruiting

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma

China
Pfizer

Terminated

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Ovarian Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Collecting Duct Carcinoma

China
Beijing Friendship Hospital
Changhai Hospital; Peking Union Medical College Hospital; Peking University Cancer...

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Locally Advanced Rectal Cancer

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Hepatocellular Carcinoma
CureVac
Syneos Health; Cromos Pharma LLC

Active, not recruiting

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Carcinoma, Adenoid Cystic | Melanoma (Skin) | Squamous Cell Carcinoma of the Skin | Carcinoma, Squamous Cell of Head and Neck

Spain, France, Austria, Germany, Russian Federation
Ratio Therapeutics, Inc.

Completed

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Prostate Cancer

United States
Tianjin Medical University Cancer Institute and...

Recruiting

PD1 and PARP for Maintenance Therapy in NSLLC

Lung Cancer

China
Sun Yat-sen University

Recruiting

Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial (AIPD-1)

Hepatocellular Carcinoma

China
Ruijin Hospital

Recruiting

A Combination Study of CAR-T Therapy in r/r B-NHL

Diffuse Large B Cell Lymphoma

China
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Cortria Corporation

Completed

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

Hyperlipidemia
Xiaorong Dong

Unknown

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NSCLC | Anlotinib | PD-1/L1 Inhibitor
The First Hospital of Jilin University

Not yet recruiting

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

Gastric Cancer | Magnetic Resonance Imaging | Neoadjuvant Chemotherapy | Neoadjuvant Immunotherapy | Tomography, X-Ray Computed
Ruijin Hospital

Not yet recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Fudan University

Active, not recruiting

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Thyroid Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer (AIPAAIAEC)

Esophageal Neoplasms

China
Fudan University

Recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Ruijin Hospital

Recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Shanghai Changzheng Hospital

Unknown

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
Shanghai Zhongshan Hospital

Unknown

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Liver Transplantation | Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China
Chen Xiaoping

Recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC

China
The Fourth Affiliated Hospital of Zhejiang University...

Recruiting

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection

Search clinical trials for: TTI-622 PD-1 Inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations